Lihua Jiang^*1, Wenchuan Yang^*1, Weishi Bian^†, Hailin Yang^*, Xia Wu^*, Yuhua Li^*, Wen Feng^*, Xuejian Liu^*

Oncology Research, Vol.27, No.1, pp. 19-27, 2019, DOI:10.3727/096504018X15193469240508

Abstract The dysregulation of microRNAs (miRNAs) plays an important function in the onset and progression of gastric cancer (GC). In addition, aberrantly expressed miRNAs affect the chemosensitivity of GC cells to chemotherapeutic drugs. Hence, miRNA-based targeted therapy might be applied to treat patients with GC exhibiting chemotherapeutic resistance. In this study, miRNA-623 (miR-623) expression was downregulated in GC tissues and cell lines. Functional analysis showed that the restored miR-623 expression could inhibit the proliferation of GC cells and enhance their chemosensitivity to 5-FU via the cell apoptosis pathway. Cyclin D1 (CCND1) was identified as a direct More >

Haisong Yang^*, Tengxiang Chen^†, Shu Xu^‡, Shiyong Zhang^*, Mengmeng Zhang^*

Oncology Research, Vol.27, No.2, pp. 219-226, 2019, DOI:10.3727/096504018X15213126075068

Abstract Breast cancer (BC) is the most common malignant tumor in women. Recently, long noncoding RNAs (lncRNAs) have been proposed as critical regulators in biological processes, including tumorigenesis. FOXC2-AS1, a single antisense oligonucleotide RNA transcribed from the negative strand of forkhead box protein C2 (FOXC2), has been identified as an oncogene in osteosarcoma. In the present study, we investigated the prognosis value and biological role of FOXC2-AS1 in BC. Our findings revealed that FOXC2-AS1 was significantly increased in BC tissues and cell lines, and Kaplan–Meier survival analysis indicated that a high level of FOXC2-AS1 was associated More >

Shihui Liu, Xiuxiu Li, Sujing Zhuang

Oncology Research, Vol.27, No.2, pp. 165-171, 2019, DOI:10.3727/096504018X15193506006164

Abstract miR-30c has been acknowledged as a tumor suppressor in various human cancers, such as ovarian cancer, gastric cancer, and prostate cancer. However, the role of miR-30c in glioblastoma (GBM) needs to be investigated. In our study, we found that the expression of miR-30c was significantly downregulated in GBM tissues and cell lines. We found that overexpression of miR-30c inhibited cellular proliferation of GBM cells in vitro and in vivo. More GBM cells were arrested in the G₀ phase after miR-30c overexpression. Moreover, we showed that miR-30c overexpression suppressed the migration and invasion of GBM cells. Mechanistically, More >

Kejun Wang^*1, Lin Yan^*1, Fen Lu^†

Oncology Research, Vol.27, No.2, pp. 157-163, 2019, DOI:10.3727/096504018X15190861873459

Abstract miR-363-3p has been shown to suppress tumor growth and metastasis in various human cancers. However, the function of miR-363-3p in osteosarcoma (OS) has not been determined. In our study, we found that the expression of miR-363-3p was significantly downregulated in OS tissues compared with adjacent normal tissues. miR-363-3p expression was associated with the poor overall survival rate of OS patients. Moreover, we found that overexpression of miR-363-3p markedly inhibited the proliferation, migration, and invasion of U2OS and MG63 cells. Moreover, we found that SOX4 was a direct target of miR-363-3p in OS cells. Overexpression of More >

Yang Zhang^*†, Min Zhu^‡, Yuanbo Sun^§, Wenyuan Li^*†, Ying Wang^*†, Weiguang Yu^¶

Oncology Research, Vol.27, No.3, pp. 379-387, 2019, DOI:10.3727/096504018X15199531937158

Abstract Breast cancer is one of the major malignancies with a mounting mortality rate in the world. Long noncoding RNA (lncRNA) cancer susceptibility candidate 2 (CASC2) has been identified to regulate the initiation and progression of multiple tumorous diseases according to previous studies. However, its biological role has been rarely reported in breast cancer. In the present study, lncRNA CASC2 was found to be significantly downregulated in breast cancer tissues and cell lines using real-time quantitative PCR. Furthermore, gain-offunction assays demonstrated that overexpression of lncRNA CASC2 significantly repressed breast cancer cell proliferation and metastasis. Moreover, CASC2 More >

Yankun Zhang^*, Wei Qian^*, Feng Feng^†, Qian Cao^*, Yanqi Li^*, Ying Hou^*, Luyang Zhang^*, Jufeng Fan^*

Oncology Research, Vol.27, No.3, pp. 371-377, 2019, DOI:10.3727/096504018X15178740729367

Abstract This study aimed to investigate the effect and underlying mechanism of lncRNA CASC2 in malignant melanoma (MM). Expression of CASC2 in MM tissues and cells was detected. A375 cells were transfected with pc-CASC2, si-CASC2, miR-18a-5p inhibitor, or corresponding controls, and then cell proliferation, migration, and invasion were detected using MTT assay, colony formation assay, and Transwell analysis, respectively. The relationship of miR-18a-5p and CASC2 or RUNX1 was detected by luciferase reporter assay. The levels of CASC2 and RUNX1 were significantly reduced in MM tissues compared with normal skin tissues or cells, while the miR-18a-5p level… More >

Hao Chen, Yi Zhang, Hai Su, Hui Shi, Qijiang Xiong, Zulu Su

Oncology Research, Vol.27, No.3, pp. 325-334, 2019, DOI:10.3727/096504018X15251282086836

Abstract It is well known that activating transcription factor 4 (ATF4) expression is closely associated with progression of many cancers. We found that miR-1283 could directly target ATF4. However, the precise mechanisms of miR-1283 in glioma have not been well clarified. Our study aimed to explore the interaction between ATF4 and miR-1283 in glioma. In this study, we found that the level of miR-1283 was dramatically decreased in glioma tissues and cell lines, the expression of ATF4 was significantly increased, and the low level of miR-1283 was closely associated with high expression of ATF4 in glioma More >

Fengyu Huang^*†, Hongjun Zhao^†, Zhaojin Du^‡, Hong Jiang^§

Oncology Research, Vol.27, No.3, pp. 293-299, 2019, DOI:10.3727/096504018X15190399381143

Abstract Previous studies have reported that miR-615 exerts a tumor suppressor role in some tumors, such as esophageal squamous cell carcinoma and non-small cell lung cancer. However, the role of miR-615 in prostate cancer has not been defined. Here we found that miR-615 was downregulated in prostate cancer tissues and cell lines. Overexpression of miR-615 in PC-3 cells significantly inhibited cellular proliferation, migration, and invasion. Moreover, overexpression of miR-615 delayed tumor growth in vivo. In terms of mechanism, we found that cyclin D2 (CCND2) is a target gene of miR-615 in prostate cancer. We showed that More >

Li Zhu^*, Lijun Xue^†

Oncology Research, Vol.27, No.6, pp. 629-634, 2019, DOI:10.3727/096504018X15228018559434

Abstract Kaempferol is a flavonoid that has been extensively investigated owing to its antitumor effects. Nevertheless, little is known about its underlying mechanisms of action. We aimed to explore the role of kaempferol in breast cancer (BC), and thus we investigated how kaempferol suppresses the growth of BC cells. The cells were treated with kaempferol, and the effects on multiple cancer-associated pathways were evaluated. The MTS assay was used to study the cell growth inhibition induced by kaempferol. The cell cycle was analyzed by flow cytometry. Western blotting was used to analyze cellular apoptosis and DNA… More >

Liping Xue^*1, Bin Lu^†1, Bibo Gao^‡, Yangyang Shi^‡, Jingqi Xu^‡, Rui Yang^‡, Bo Xu^‡, Peng Ding^‡

Oncology Research, Vol.27, No.5, pp. 557-564, 2019, DOI:10.3727/096504018X15264647024196

Abstract Because of the characteristics of high invasiveness, relapse, and poor prognosis, the management of malignant gliomas has always been a great challenge. Nod-like receptor (NLR) family pyrin domain containing 3 (NLRP3) is a crucial component of the NLRP3 inflammasome, a multiprotein complex that can trigger caspase 1/interleukin-1 (IL-1)-mediated inflammatory response once activated and participates in the pathogeny of diverse inflammatory diseases as well as cancers. We examined the function of NLRP3 in the development of glioma. Glioma cells were treated with NLRP3 interference or overexpression vectors, recombinant IL-1 , IL-1 antibody, and NF- B inhibitor.… More >